Brief: Cytodyn Says First Patient In Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction In Circulating Tumor Cells
12/11/2019 01:06
Nov 11 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN - FIRST PATIENT IN TRIPLE-NEGATIVE METASTATIC
BREAST
CANCER TRIAL SHOWS SIGNIFICANT REDUCTION IN CIRCULATING TUMOR
CELLS,REDUCED TUMOR SIZE
Source text for Eikon: ID:nGNXbJFKDk
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer